


La molécule du mois - What molecule am I ?



Rucaparib

Rucaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor specifically indicated as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer. PARP's play a role in DNA repair. *In vitro* studies have shown that rucaparib may involve inhibition of PARP enzymatic activity resulting in preventing DNA repair in tumor cells, particularly those tumors that have defective BRCA.

Rucaparib was approved by FDA in December 2016 (Rubraca®) as the first-in-class pharmaceutical drug targeting the DNA repair enzyme poly-ADP ribose polymerase (PARP) for the treatment of advanced ovarian cancer.

Contribution : David MONTOIR & Abdallah HAMZE July 2017